


Lysaker,  27 November 2015 - In accordance with the authorization granted by the
Annual  General Meeting  13th May 2014, the  Board of  Directors of  PCI Biotech
Holding ASA has awarded a total of 110,000 options to key employees. Each option
gives  the right  to subscribe  for or  acquire one  share per option (after PCI
Biotech  Holding ASA's  choice), at  a strike  price of  NOK 5.21, equal  to the
volume  weighted average price (VWAP) for the  last 5 days of trade prior to the
grant date. The options can be exercised with 1/3 of the options after one year,
further  1/3 after two years and  the last third after  three years. The options
are lapsing in Q3 2020.

Of  these options,  9,000 options were  allotted to  Per Walday,  CEO. After the
allocation,  Per Walday holds  a total portfolio  of 105,000 unexercised options
and 44,019 shares.

7,500 options  were  allotted  to  Kristin  Eivindvik, PD. After the allocation,
Kristin  Eivindvik  holds  a  total  portfolio of 24,500 unexercised options and
13,235 shares.

6,000 options  were allotted to Gaël L'Hévéder, CBDO. After the allocation, Gaël
L'Hévéder  holds  a  total  portfolio  of 91,000 unexercised options and 10,000
shares.

6,000 options  were allotted to Anders Høgset, CSO. After the allocation, Anders
Høgset holds a total portfolio of 77,000 unexercised options and 47,977 shares.

6,000 options were allotted to Ronny Skuggedal, CFO. After the allocation, Ronny
Skuggedal  holds  a  total  portfolio  of 66,000 unexercised options and 15,000
shares.

For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1969821] 
    